Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a...
Company
Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...
Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs
Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...
Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership
Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...
Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce
Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...
Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...
Biosecure Act Faces Opposition from Senior House Democrat Jim McGovern
The trajectory of the US Biosecure Act through the House of Representatives encountered unexpected turbulence...
China’s CDE Releases 86th Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has unveiled its 86th roster of reference preparations for...
Akeso’s Ivonescimab Shows Promising Results in Phase III Clinical Trial for Hepatocellular Carcinoma
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced that its first-in-class...
AstraZeneca Faces Investigation in China Over Data Privacy and Unapproved Drugs
AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, is reportedly under the spotlight in Shenzhen,...
U.S. House of Representatives to Review the Biosecure Act Amid Legislative Hurdles
The U.S. House of Representatives is slated to take up the contentious Biosecure Act the...
Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...
Euroapi to Downsize API Production, Citing Asian Competition and Market Stagnation
Euroapi (EPA: EAPI), a French company and a spinoff from Sanofi established in 2022, has...
Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into...
Sinocelltech’s Herpes Zoster Vaccine SCTV04C Clears NMPA for Clinical Trial
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has received approval from...
Voyager Therapeutics Secures Licensing Deal with Novartis for Gene Therapy Capsid
Voyager Therapeutics Inc. (NASDAQ: VYGR), a U.S.-based biotechnology company, has announced a licensing agreement with...
Fujirebio’s HBsAg Detection Kit Receives NMPA Approval, Enhances Early Diagnosis Capabilities
Fujirebio Inc., a leading diagnostic company based in Japan, has received approval from China’s National...
Jiangsu Kanion Pharmaceutical Gets NMPA Go-Ahead for Psoriasis Drug Clinical Trial
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a prominent pharmaceutical company based in China, has...